[go: up one dir, main page]

AU6877991A - A method of inactivating human immunodeficiency virus - Google Patents

A method of inactivating human immunodeficiency virus

Info

Publication number
AU6877991A
AU6877991A AU68779/91A AU6877991A AU6877991A AU 6877991 A AU6877991 A AU 6877991A AU 68779/91 A AU68779/91 A AU 68779/91A AU 6877991 A AU6877991 A AU 6877991A AU 6877991 A AU6877991 A AU 6877991A
Authority
AU
Australia
Prior art keywords
immunodeficiency virus
human immunodeficiency
inactivating human
inactivating
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68779/91A
Inventor
Lionel J. G Filion
Rene C Gaudreault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
University of Ottawa
Original Assignee
Universite Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Laval filed Critical Universite Laval
Publication of AU6877991A publication Critical patent/AU6877991A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/252Naphthacene radicals, e.g. daunomycins, adriamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU68779/91A 1989-11-28 1990-11-28 A method of inactivating human immunodeficiency virus Abandoned AU6877991A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44223489A 1989-11-28 1989-11-28
US442234 1989-11-28

Publications (1)

Publication Number Publication Date
AU6877991A true AU6877991A (en) 1991-06-26

Family

ID=23756040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68779/91A Abandoned AU6877991A (en) 1989-11-28 1990-11-28 A method of inactivating human immunodeficiency virus

Country Status (2)

Country Link
AU (1) AU6877991A (en)
WO (1) WO1991007989A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0686043B1 (en) * 1993-02-24 1999-06-23 WANG, Jui, H. Compositions and methods of application of reactive antiviral polymers
DE19513888A1 (en) * 1995-04-19 1996-10-24 Focke & Co Method and device for applying markings, in particular color markings, to film webs
DE19847362A1 (en) * 1998-10-14 2000-04-20 Deutsches Krebsforsch New polycyclic aromatic compound-protein conjugates, useful for detection and/or treatment of diseased tissue, e.g. tumors or inflammation sites
JP2004538342A (en) * 2001-03-27 2004-12-24 フイルメニツヒ ソシエテ アノニム Compounds for controlled release of active compounds
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
AU2004289953B2 (en) 2003-06-18 2008-09-25 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63310830A (en) * 1987-06-10 1988-12-19 Meiji Seika Kaisha Ltd Antiretroviral agent

Also Published As

Publication number Publication date
WO1991007989A1 (en) 1991-06-13

Similar Documents

Publication Publication Date Title
AU5726694A (en) Human immunodeficiency virus decoy
AU4750390A (en) Virus inactivated blood product and method
AU5789290A (en) Grasping forceps
AU7746487A (en) Surgical prosthesis
AU5980790A (en) Prosthesis
AU4028895A (en) Vaccine and treatment method of Human Immunodeficiency Virus
ZA936592B (en) Nutrition for persons infected with human immunodeficiency virus
AU3413389A (en) Method of treating retrovirus infection
AU6068290A (en) Invalid walker
AU5449590A (en) Anti-hiv drug
AU5848794A (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
AU3775789A (en) A method of evaluating recombinant vaccines against immunodeficiency virus
AU6291290A (en) Prosthesis
AU5568290A (en) Method of suppressing hiv infection
US5011841B1 (en) Treatment of depression
AU6877991A (en) A method of inactivating human immunodeficiency virus
AU3836489A (en) Treatment of immunodeficiency
AU3964789A (en) Filtering procedure
AU5836390A (en) Human lymphoma-associated virus
AU4034289A (en) Disposable glove
AU7516494A (en) Oligomers for modulating human immunodeficiency virus
EP0414569A3 (en) Three-liquid-phase epoxidation of perfluoroolefins
AU5306590A (en) Method of killing pests
AU7737991A (en) Medical uses of m-csf
AU5940890A (en) Prosthetic limb